Ofev Corrects Blood Vessel Abnormalities Associated with Lung Fibrosis, Study Suggests

Ofev Corrects Blood Vessel Abnormalities Associated with Lung Fibrosis, Study Suggests

Ofev (nintedanib) can counter lung fibrosis by correcting abnormalities in lung blood-vessel structure, according to a German study in mice. The research suggests that fibrosis, or tissue scarring, and mechanisms involved in blood vessel formation interact in the progression of the disease. Researchers at the Johannes Gutenberg University Medical Center in Mainz studied…

Two Medical Centers Adopt ZappRx’s Digital Platform to Ease Prescription of Specialty Medications

ZappRx’s new digital platform for prescribing specialty medications, including therapies to treat pulmonary fibrosis, can now be used at two centers with expertise in respiratory conditions —  Arizona Pulmonary Specialists and Harbor-UCLA Medical Center. The platform was designed to speed up and simplify the complex process required to order…

Pulmonary Fibrosis Symptoms: Fatigue

There are many symptoms associated with pulmonary fibrosis (PF), but fatigue is often cited as one of the most difficult to deal with by those living with the disease. MORE: Nine steps for managing pulmonary fibrosis Fatigue in pulmonary fibrosis goes much further than simply being tired and often can’t…

Samumed’s Candidate PF Therapy, SM04646, Found to Be Well-tolerated and Safe in Phase 1 Trial

Samumed’s nebulized inhalation solution SM04646, a candidate therapy to treat idiopathic pulmonary fibrosis (IPF), was found to be well-tolerated and to cause no serious adverse effects in a Phase 1 trial of healthy individuals in Australia. These results support the launch of future clinical trials to test the drug’s efficacy in IPF patients. According to…